What insurance policy changes affect code F51.03?

There are 3 tracked policy changes affecting code F51.03, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F51.03?

Payers that have issued tracked updates for code F51.03 include: Aetna.

How do I get notified when code F51.03 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F51.03. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F51.03?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

F51.03 Insurance Policy Changes

ICD-10 F51.03 is officially defined as "Paradoxical insomnia." code F51.03 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F51.03 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) (CPB 0330, reviewed 2026-05-20)
Aetna considers the multiple sleep latency test (MSLT) and maintenance of wakefulness test (MWT) medically necessary to evaluate symptoms of narcolepsy to confirm the diagnosis, and for suspected idiopathic hypersomnia to help differentiate it from narcolepsy. A repeat MSLT or MWT is medically necessary only if the initial test was invalid or uninterpretable, was affected by extraneous circumstances or lacked study conditions, or the patient is suspected to have narcolepsy and an earlier test did not provide polygraphic confirmation. Home MSLT and single nap studies are experimental, investigational or unproven, as are these tests for other indications, including attention-deficit/hyperactivity disorder, chronic fatigue syndrome, insomnia, obstructive sleep apnea syndrome, restless leg syndrome, psychiatric hypersomnolence, and neurologic disorders other than narcolepsy such as dementia and Parkinson's disease.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.
Aetna · Identified Aug 12, 2026Medium impact
Acoustic Pharyngometers and SNAP Testing System (CPB 0336, reviewed 2026-05-20)
Aetna considers SNAP Testing using 3 or more channels a medically necessary device for home diagnosis of obstructive sleep apnea in adults, according to the criteria in CPB 0004, and lists HCPCS G0400, a home sleep test with a type IV portable monitor using a minimum of 3 channels, as covered for adults only when selection criteria are met. Acoustic pharyngometry, such as the Eccovision Acoustic Pharyngometer, and SNAP Testing System versions using fewer than 3 channels are considered experimental, investigational, or unproven for screening, diagnosis, treatment planning, or prediction of surgical success in persons with suspected or known obstructive sleep apnea, and for all other indications. The policy lists no specific CPT or HCPCS code for acoustic pharyngometry.

Watch F51.03

Get one email when a payer policy names F51.03, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) (CPB 0330, reviewed 2026-05-20)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

Acoustic Pharyngometers and SNAP Testing System (CPB 0336, reviewed 2026-05-20)

What insurance policy changes affect code F51.03?

Which payers have updated policy for code F51.03?

How do I get notified when code F51.03 policy changes?

Why do payers change policies for code F51.03?